Skip to content
TrialScanner

NCT04857359

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Phase 2/Phase 3TerminatedADXNLead

Registry record

Lead sponsor
Addex Pharma S.A.
Conditions
Parkinson Disease; Dyskinesia, Drug-Induced; Dyskinesias
Primary completion
Jun 17, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04857359 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04857359: Dipraglurant (ADX48621) for... | TrialScanner